Latest Breaking News On - Katja margell - Page 8 : comparemela.com

Hansa Biopharma achieves Great Place to Work certification for second consecutive year

Hansa Biopharma achieves Great Place to Work certification for second consecutive year
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Hansa biopharmaPrnewswire hansa biopharmaKlaus sindahlKatja margellCompanies to workHead of corporate communicationsNasdaq stockholmGreat placesGreat placeBest workplacesWork for

Hansa Biopharma announces reimbursement in the Netherlands of Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

Hansa Biopharma announces reimbursement in the Netherlands of Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United kingdomHansa biopharmaPrnewswire hansa biopharmaKlaus sindahlHenk doude van troostwijkKatja margellEuropean unionEuropean medicines agencyErasmus medical centerEuropean medicines agency priorityHead of corporate communicationsNasdaq stockholmHenk doudeSenior vice presidentChief commercial officerInvestor relations

Hansa Biopharma Interim Report Jan-June 2021

Hansa Biopharma Interim Report Jan-June 2021
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesNorthwestern memorial hospitalUnited kingdomHilary maloneHansa biopharmaPrnewswire hansa biopharmaRoberta montgomeryKlaus sindahlDonato spotaKatja margellUniversity of alabamaTherapies councilReata pharmaceuticalsValo health incLangone transplant institute

Hansa Biopharma announces long term follow-up data demonstrating 3-year graft survival of 84% after imlifidase treatment and transplantation

Hansa Biopharma announces long term follow-up data demonstrating 3-year graft survival of 84% after imlifidase treatment and transplantation
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesHansa biopharmaKlaus sindahlKatja margellChristian kjellmanEuropean unionEuropean medicines agencyEuropean medicines agency priorityEuropean medicine agencyHead of corporate communicationsNasdaq stockholmAmerican journalChief scientific officerHuman leukocyte antigensEuropean marketing authorizationEuropean medicine

Hansa Biopharma to host conference call to provide interim results for first half 2021 and Business Update

Hansa Biopharma to host conference call to provide interim results for first half 2021 and Business Update
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomHansa biopharmaPrnewswire hansa biopharmaKlaus sindahlDonato spotaKatja margellHead of corporate communicationsDanske bank life scienceNasdaq stockholmWilliam blair biotech focus conferenceHandelsbanken life science innovation seminarPenser accessPareto healthcare conferenceMorganstanley global healthcare conferenceAnnual global investment conference